Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | STK17B | O94768 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6812940 | 1.00 | APP (0.66) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6614747 | 0.96 | APP (0.68) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6809157 | 0.96 | APP (0.68) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6802869 | 0.93 | APP (0.63) | APPSTK17B | |
| SCHEMBL6802871 | 0.93 | APP (0.63) | APPSTK17B | |
| SCHEMBL6808169 | 0.91 | APP (0.72) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6808167 | 0.91 | APP (0.72) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6610601 | 0.90 | APP (0.70) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6812966 | 0.90 | APP (0.70) | APPSTK17BKDM4EMEN1NPC1 | |
| SCHEMBL6812733 | 0.88 | APP (0.74) | APPSTK17BKDM4EMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | APP 3533/4885STK17B 266/4885KDM4E 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.